Biotechnology News and Research

RSS

Whooping cough outbreak despite vaccination

...

21 Mar 2012

MD Anderson, Transgenomic partner to evaluate use of ICE COLD-PCR

Transgenomic, Inc. today announced that it has begun a collaboration with The University of Texas MD Anderson Cancer Center to evaluate the use of the Company's very high sensitivity ICE COLD-PCR mutation detection technology in analysis of DNA isolated from circulating tumor cells (CTCs) in blood samples from patients with advanced cancer.

21 Mar 2012

GeoVax enters into definitive agreements to sell Series A convertible preferred stock

GeoVax Labs, Inc., an Atlanta-based biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, announced today that it has entered into definitive agreements with certain institutional investors, pursuant to which the Company has agreed to sell shares of its Series A convertible preferred stock at an aggregate purchase price of approximately $2.2 million and Series A warrants to purchase up to an aggregate of 2,933,333 shares of GeoVax common stock with an exercise price of $1.00 per share and a term of five years.

21 Mar 2012

ISCO fourth quarter revenue increases 110% to $1.1 million

International Stem Cell Corporation today announced year-end financial results for the year ended December 31, 2011.

21 Mar 2012

Sharp rise recorded in cases of new strain of whooping cough: New genotype may be evading vaccine’s protective effects

Australia’s prolonged whooping cough epidemic has entered a disturbing new phase, with a study showing a new strain or genotype may be responsible for the sharp rise in the number of cases.

20 Mar 2012

n3D releases new 24-well Bio-Assembler

Only days after Rainbow BioSciences closed a deal to acquire an equity interest in Nano3D Biosciences, n3D announced the release of its groundbreaking new 24-well Bio-Assembler.

20 Mar 2012

Mayo Clinic researchers train mouse immune systems to eradicate skin cancer from within

Mayo Clinic researchers have trained mouse immune systems to eradicate skin cancer from within, using a genetic combination of human DNA from melanoma cells and a cousin of the rabies virus. The strategy, called cancer immunotherapy, uses a genetically engineered version of the vesicular stomatitis virus to deliver a broad spectrum of genes derived from melanoma cancer cells directly into tumors.

20 Mar 2012

Synthes signs license and development agreement with Kuros

Kuros Biosurgery AG, a biotechnology company focused on the development of novel biomaterials and bioactive-biomaterial combination products for trauma, wound and spinal indications has signed a license and development agreement with Synthes, Inc. a leading global medical device company.

20 Mar 2012

Moraga announces publication of its blood-derived BLSCs patent with EPO

Moraga Biotechnology Corporation, an adult stem cell company based in Culver City, California, announces the publication of its blood-derived Blastomere-Like Stem Cells (BLSCs) patent with the European Patent Office.

20 Mar 2012

MabCure, CUNY CAT partner to evaluate monoclonal antibodies against ovarian cancer cells

MabCure Inc., leading developer of antibody based technology for the diagnosis and treatment of Ovarian, Prostate, Colorectal and other cancers today announced it has entered into an agreement with the City University of New York Center for Advanced Technology (CUNY CAT) to evaluate its monoclonal antibodies against ovarian cancer cells as diagnostic reagents.

19 Mar 2012

Alnylam commences dosing in ALN-TTR02 Phase I clinical trial for TTR-mediated amyloidosis

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has initiated dosing in its Phase I clinical trial with ALN-TTR02, an RNAi therapeutic targeting the transthyretin (TTR) gene for the treatment of TTR-mediated amyloidosis (ATTR). The study is aimed at evaluating the safety and tolerability of ALN-TTR02 in healthy volunteers.

19 Mar 2012

RBCC's new agreement with n3D could help develop stem-cell therapies

As global demand for innovative new stem-cell therapies grows by the day, Rainbow BioSciences' new agreement with n3D Biosciences could help to bring these therapies to market faster than ever before.

19 Mar 2012

Convergence initiates CNV1014802 Phase II study in trigeminal neuralgia

Convergence Pharmaceuticals Limited, the company focused on the development of novel and high value analgesic medicines, today announced that the Phase II proof of concept study for CNV1014802 for the treatment of pain associated with trigeminal neuralgia (TN) has started.

19 Mar 2012

AstraZeneca CEO to take part in panel discussion on Ethical Practices in the Pharmaceutical Sector

David Brennan, CEO of AstraZeneca, will take part in the plenary session panel discussion on "Ethical Practices in the Pharmaceutical Sector" at the EuroMeeting 2012 in Copenhagen on Monday 26 March.

19 Mar 2012

DA4S's fifth annual networking conference and EXPO to take place from May 21-23

On May 21-23, 2012, Diversity Alliance for Science, Inc., a non-profit organization created to support, mentor, and develop minority-, woman-, veteran/service-disabled-, HUBZone-, and LGBT-owned, life sciences businesses, will host its fifth annual networking conference and EXPO event.

17 Mar 2012

Positive data from VBL Therapeutics' VB-201 Phase 2 study on psoriasis, atherosclerosis

VBL Therapeutics, a clinical stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced that a Phase 2 sub-study of VB-201 in moderate to severe psoriasis patients with cardiovascular risk has successfully achieved its primary endpoint demonstrating a statistically significant reduction in vascular inflammation associated with atherosclerotic lesions as measured by PET-CT imaging.

17 Mar 2012

Tarsa advances OSTORA NDA filing through $28M Series B financing

Tarsa Therapeutics, Inc. today announced completion of a $28 million Series B equity financing led by new investor Foresite Capital.

17 Mar 2012

Repligen total revenue increases to $7,165,000 for quarter ended December 31, 2011

Repligen Corporation today reported financial results for the quarter and nine-month fiscal year ended December 31, 2011.

17 Mar 2012

UAB researchers develop new vehicle to release proteins with therapeutic effects

UAB researchers developed a new vehicle to release proteins with therapeutic effects. The vehicles are known as "bacteria inclusion bodies", stable insoluble nanoparticles which are found normally in recombinant bacteria.

17 Mar 2012

Epigenetic designer baby may prove to be a non-starter

Epigenetics is the new hip science. Time Magazine's front cover and article, 'Why your DNA isn't your Destiny' from January 2010 explains why. Its more explicit subtitle provided the hook - 'The new science of epigenetics reveals how the choices you make can change your genes - and those of your kids'. Who wouldn't be interested in this?

16 Mar 2012

Biotechnology News and Research

Whooping cough outbreak despite vaccination

MD Anderson, Transgenomic partner to evaluate use of ICE COLD-PCR

GeoVax enters into definitive agreements to sell Series A convertible preferred stock

ISCO fourth quarter revenue increases 110% to $1.1 million

Sharp rise recorded in cases of new strain of whooping cough: New genotype may be evading vaccine’s protective effects

n3D releases new 24-well Bio-Assembler

Mayo Clinic researchers train mouse immune systems to eradicate skin cancer from within

Synthes signs license and development agreement with Kuros

Moraga announces publication of its blood-derived BLSCs patent with EPO

MabCure, CUNY CAT partner to evaluate monoclonal antibodies against ovarian cancer cells

Alnylam commences dosing in ALN-TTR02 Phase I clinical trial for TTR-mediated amyloidosis

RBCC's new agreement with n3D could help develop stem-cell therapies

Convergence initiates CNV1014802 Phase II study in trigeminal neuralgia

AstraZeneca CEO to take part in panel discussion on Ethical Practices in the Pharmaceutical Sector

DA4S's fifth annual networking conference and EXPO to take place from May 21-23

Positive data from VBL Therapeutics' VB-201 Phase 2 study on psoriasis, atherosclerosis

Tarsa advances OSTORA NDA filing through $28M Series B financing

Repligen total revenue increases to $7,165,000 for quarter ended December 31, 2011

UAB researchers develop new vehicle to release proteins with therapeutic effects

Epigenetic designer baby may prove to be a non-starter

Biotechnology eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News